Memorial Sloan Kettering Cancer Center-led researchers have identified a small molecule called gliocidin that kills ...

A new study from scientists at the UCLA Health Jonsson Comprehensive Cancer Center helps explain why glioblastoma, one of the ...

Sonodynamic therapy doubled the median overall survival to 15.7 months and tripled progression-free survival to 5.5 months in ...

Glioblastoma typically kills within 18 months, but a new type of treatment has kept Nadya El-Afandi's scans clear 17 months ...

A fourth of patients with TRK fusion primary central nervous system tumors responded to the TRK inhibitor larotrectinib ...

Experts debate the value of the new agent for low-grade gliomas with an IDH1 or IDH2 mutation. Some have hailed the drug a ...

The global glioblastoma multiforme treatment market size was valued at USD 2.78 billion in 2024 and is expected to reach around USD 5.68 billion by 2033, registering a CAGR of 8.23% from 2024 to 2033.

Adaptive therapy is a novel approach to malignant glioma that involves decreasing treatment dose as the tumor responds and increasing the dose as the tumor grows. Differentiation therapy causes ...

Nadya El-Afandi was nearing the end of breast cancer treatment when she received earth-shattering news: Doctors had diagnosed her with glioblastoma, a rapidly growing and aggressive brain tumor.

Executive Vice President, director of the Vaccine & Immunotherapy Center and W.W. Smith Charitable Trust Distinguished ...